Supriya Lifescience Limited

About the company

From being incorporated in 1987 as a partnership firm which makes chemicals, Supriya Lifescience has evolved into one of the key manufacturers and suppliers of active pharmaceutical ingredients (APIs). Also, over the last three years, the company has posted strong financial performance. Its revenue and profit have risen steadily, aided by growth in domestic and export pharma markets. This API manufacturer is now all set to launch its ₹700 crore IPO and list on the exchanges. **Key highlights** * Has niche 38 APIs which are used in diverse therapeutic segments including antihistamine, analgesic and anaesthetic  * As of October 2021, its products were exported to 1,296 clients across 86 countries * Around 77% of its revenue came from exports in FY21 **Strengths** * Accounted for 45-55% and 65-70%, respectively, of the Chlorpheniramine Maleate and Ketamine Hydrochloride exports from India between FY17-FY21 * Increased share in Salbutamol Sulphate exports from 25-30% in FY17 to 35-40% in FY21   **Risks** * Operates in a highly regulated industry. Facilities and products are subject to periodic inspections or audits * High dependence on its 10 APIs, which account for over 80% of revenue **Opportunities** * The global pharmaceutical market is expected to grow at a CAGR of 6% to ₹1,730 billion by 2025  * The domestic formulations market is expected to grow at a CAGR of 11% over the next five years  

Financial performance (₹ Cr)

IPO Roadmap / Timeline

1. IPO Opens

   Completed
   16 Dec 2021

   Bidding starts for all investor categories

2. IPO Closes

   Completed
   20 Dec 2021

   Last day to place your bid

3. Basis of Allotment

   Completed
   18 Dec 2021

   Share allotment finalised

4. Refund Initiation

   Completed
   24 Dec 2021

   Refunds credited for non-allottees

5. Credit to Demat

   Completed
   23 Dec 2021

   Allotted shares credited to demat account

6. Listing on Exchange

   Completed
   28 Dec 2021

   Shares list on NSE / BSE

Post-close dates are indicative as per SEBI T+3 listing framework and may change per registrar updates.